% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Phipps:153797,
author = {A. I. Phipps and E. Alwers$^*$ and T. Harrison and B.
Banbury and H. Brenner$^*$ and P. T. Campbell and J.
Chang-Claude$^*$ and D. Buchanan and A. T. Chan and A. B.
Farris and J. C. Figueiredo and S. Gallinger and G. G. Giles
and M. Jenkins and R. L. Milne and P. A. Newcomb and M. L.
Slattery and M. Song and S. Ogino and S. H. Zaidi and M.
Hoffmeister$^*$ and U. Peters},
title = {{A}ssociation {B}etween {M}olecular {S}ubtypes of
{C}olorectal {T}umors and {P}atient {S}urvival, {B}ased on
{P}ooled {A}nalysis of 7 {I}nternational {S}tudies.},
journal = {Gastroenterology},
volume = {158},
number = {8},
issn = {0016-5085},
address = {Philadelphia, Pa. [u.a.]},
publisher = {Saunders},
reportid = {DKFZ-2020-00463},
pages = {2158-2168.e4},
year = {2020},
note = {2020 Jun;158(8):2158-2168.e4 / #EA:C070#LA:C070#},
abstract = {The heterogeneity among colorectal tumors is probably due
to differences in developmental pathways and might associate
with patient survival times. We studied the relationship
among markers of different subtypes of colorectal tumors and
patient survival.We pooled data from 7 observational
studies, comprising 5010 patients with colorectal cancer.
All the studies collected information on microsatellite
instability (MSI), CpG island methylator phenotype (CIMP),
and mutations in KRAS and BRAF in tumors. Tumors with
complete marker data were classified as type 1 (MSI high,
CIMP positive, with pathogenic mutations in BRAF but not
KRAS), type 2 (not MSI high, CIMP positive, with pathogenic
mutations in BRAF but not KRAS); type 3 (not MSI high or
CIMP, with pathogenic mutations in KRAS but not BRAF); type
4 (not MSI-high or CIMP, no pathogenic mutations in BRAF or
KRAS), or type 5 (MSI-high, no CIMP, no pathogenic mutations
in BRAF or KRAS). We used Cox regression to estimate hazard
ratios (HR) and $95\%$ CIs for associations of these
subtypes and tumor markers with disease-specific survival
(DSS) and overall survival (OS) times, adjusting for age,
sex, stage at diagnosis, and study population.Patients with
type 2 colorectal tumors had significantly longer time of
DSS than patients with type 4 tumors (HRDSS, 1.66; $95\%$
CI, 1.33-2.07), regardless of sex, age, or stage at
diagnosis. Patients without MSI-high tumors had
significantly shorter time of DSS compared to patients with
MSI-high tumors (HRDSS, 0.42; $95\%$ CI, 0.27-0.64),
regardless of other tumor markers or stage, or patient sex
or age.In a pooled analysis of data from 7 observational
studies of patients with colorectal cancer, we found that
tumor subtypes, defined by combinations of 4 common tumor
markers, were associated with differences in survival time.
Colorectal tumor subtypes might therefore be used in
determining patients' prognoses.},
cin = {C070 / C120 / HD01 / C020},
ddc = {610},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
I:(DE-He78)HD01-20160331 / I:(DE-He78)C020-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:32088204},
doi = {10.1053/j.gastro.2020.02.029},
url = {https://inrepo02.dkfz.de/record/153797},
}